Reversing regulatory safeguards: Targeting the ATR pathway to overcome PARP inhibitor resistance

被引：1

作者：

Lin, Xixi ^{[1
,2
]}

Qiu, Ye ^{[1
,2
]}

Soni, Aashish ^{[1
,2
]}

Stuschke, Martin ^{[1
,3
]}

Iliakis, George ^{[1
,2
]}

机构：

[1] Univ Duisburg Essen, Univ Hosp Essen, Dept Radiat Therapy, Div Expt Radiat Biol, D-45147 Essen, Germany

[2] Univ Duisburg Essen, Univ Hosp Essen, Inst Med Radiat Biol, D-45147 Essen, Germany

[3] German Canc Res Ctr, Partner Site Univ Hosp Essen, German Canc Consortium DKTK, D-45147 Essen, Germany

来源：

MOLECULAR THERAPY ONCOLOGY | 2025年 / 33卷 / 01期

关键词：

STRAND-BREAK REPAIR; REPLICATION FORK STABILITY; HOMOLOGOUS RECOMBINATION; SYNTHETIC LETHALITY; LUNG-CANCER; CHECKPOINT; OLAPARIB; CELLS; PHOSPHORYLATION; DEGRADATION;

D O I：

10.1016/j.omton.2025.200934

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The development of poly (ADP-ribose) polymerase inhibitors (PARPis) is widely considered a therapeutic milestone in the management of BRCA1/2-deficient malignancies. Since a growing number of cancer treatment guidelines include PARPis, the inevitably emerging PARPi resistance becomes a serious limitation that must be addressed. Targeting the DNA damage response signaling kinase, ATR (ataxia telangiectasia and rad3-related serine/threonine kinase), activated in response to PARPi-induced replication stress, represents a promising approach in fighting PARPi-resistant cancers. The success of this combination therapy in preclinical models has inspired efforts to translate its potential through extensive clinical research and clinical trials. However, the available clinical evidence suggests that PARPi/ATRi combinations have yet to reach their anticipated therapeutic potential. In this review, we summarize work elucidating mechanisms underpinning the effectiveness of ATRi in fighting PARPi resistance and review translational studies reporting efficacy in different types of cancer. Finally, we discuss potential biomarkers of patient selection for customized combinations of PARPi/ATRi treatments.

引用

页数：14

共 25 条

[11] Polymer Nanoparticles Overcome Drug Resistance by a Dual-Targeting Apoptotic Signaling Pathway in Breast Cancer [J].

Li, Ning ;

Gao, Dong ;

Li, Chen ;

Wang, Baiqi ;

Li, Boying ;

Bao, Benkai ;

Wu, Manman ;

Li, Mengying ;

Xing, Chengfen .

ACS APPLIED MATERIALS & INTERFACES, 2022, 14 (20) :23117-23128

[12] Targeting ARPC1B Overcomes Immune Checkpoint Inhibitor Resistance in Glioblastoma by Reversing Protumorigenic Macrophage Polarization [J].

Liu, Tianqi ;

Sun, Tao ;

Chen, Xin ;

Wu, Jianqi ;

Sun, Xiaoqian ;

Liu, Xing ;

Yan, Haixu ;

Fu, Qiang ;

Fan, Zirong ;

Wang, Xiangyu ;

Cheng, Peng ;

Cheng, Wen ;

Wu, Anhua .

CANCER RESEARCH, 2025, 85 (07) :1236-1252

[13] Cell cycle checkpoints and beyond: Exploiting the ATR/CHK1/WEE1 pathway for the treatment of PARP inhibitor-resistant cancer [J].

Gupta, Nitasha ;

Huang, Tzu-Ting ;

Horibata, Sachi ;

Lee, Jung-Min .

PHARMACOLOGICAL RESEARCH, 2022, 178

[14] Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib [J].

Zhu, Lei ;

Chen, Zhen ;

Zang, Hongjing ;

Fan, Songqing ;

Gu, Jiajia ;

Zhang, Guojing ;

Sun, Kevin D-Y ;

Wang, Qiming ;

He, Yong ;

Owonikoko, Taofeek K. ;

Ramalingam, Suresh S. ;

Sun, Shi-Yong .

CANCER RESEARCH, 2021, 81 (18) :4822-4834

[15] Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer [J].

Mehta, Anita K. ;

Cheney, Emily M. ;

Hartl, Christina A. ;

Pantelidou, Constantia ;

Oliwa, Madisson ;

Castrillon, Jessica A. ;

Lin, Jia-Ren ;

Hurst, Katie E. ;

de Oliveira Taveira, Mateus ;

Johnson, Nathan T. ;

Oldham, William M. ;

Kalocsay, Marian ;

Berberich, Matthew J. ;

Boswell, Sarah A. ;

Kothari, Aditi ;

Johnson, Shawn ;

Dillon, Deborah A. ;

Lipschitz, Mikel ;

Rodig, Scott ;

Santagata, Sandro ;

Garber, Judy E. ;

Tung, Nadine ;

Yelamos, Jose ;

Thaxton, Jessica E. ;

Mittendorf, Elizabeth A. ;

Sorger, Peter K. ;

Shapiro, Geoffrey I. ;

Guerriero, Jennifer L. .

NATURE CANCER, 2021, 2 (01) :66-+

[16] Two novel strategies to overcome the resistance to ALK tyrosine kinase inhibitor drugs: Macrocyclic inhibitors and proteolysis-targeting chimeras [J].

Song, Xiaoling ;

Zhong, Hui ;

Qu, Xiaojuan ;

Yang, Linsong ;

Jiang, Biao .

MEDCOMM, 2021, 2 (03) :341-350

[17] ATF3-induced activation of NF-κB pathway results in acquired PARP inhibitor resistance in pancreatic adenocarcinoma [J].

Liu, Yang ;

Cao, Yizhi ;

Liu, Pengyi ;

Zhai, Shuyu ;

Liu, Yihao ;

Tang, Xiaomei ;

Lin, Jiayu ;

Shi, Minmin ;

Qi, Debin ;

Deng, Xiaxing ;

Zhu, Youwei ;

Wang, Weishen ;

Shen, Baiyong .

CELLULAR ONCOLOGY, 2024, 47 (03) :939-950

[18] PARP1 Inhibitor Combined With Oxaliplatin Efficiently Suppresses Oxaliplatin Resistance in Gastric Cancer-Derived Organoids via Homologous Recombination and the Base Excision Repair Pathway [J].

Li, Huafu ;

Wang, Chunming ;

Lan, Linxiang ;

Wu, Wenhui ;

Evans, Ian ;

Ruiz, E. Josue ;

Yan, Leping ;

Zhou, Zhijun ;

Oliveira, Joaquim M. ;

Reis, Rui L. ;

Hu, Zhenran ;

Chen, Wei ;

Behrens, Axel ;

He, Yulong ;

Zhang, Changhua .

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9

[19] Modulation of FLT3-ITD Localization and Targeting of Distinct Downstream Signaling Pathways as Potential Strategies to Overcome FLT3-Inhibitor Resistance [J].

Fleischmann, Maximilian ;

Fischer, Mike ;

Schnetzke, Ulf ;

Fortner, Colin ;

Kirkpatrick, Joanna ;

Heidel, Florian H. ;

Hochhaus, Andreas ;

Scholl, Sebastian .

CELLS, 2021, 10 (11)

[20] Discovery of a novel Wnt inhibitor DK419: Reversing temozolomide resistance in glioblastoma by switching off Wnt/β-catenin signaling pathway to inhibit MGMT expression [J].

Bai, Peiying ;

Wang, Peng ;

Ren, Ting ;

Tang, Qing ;

Zhang, Na ;

Zhao, Lijiao ;

Zhong, Rugang ;

Sun, Guohui .

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2025, 288

← 1 2 3 →